ECOR - エレクトロコア (electroCore Inc.) エレクトロコア

 ECORのチャート


 ECORの企業情報

symbol ECOR
会社名 ElectroCore Inc (エレクトロコア)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ElectroCore Inc. formerly ElectroCore LLC is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology psychiatry gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache) and the associated chronic co-morbidities of gastric motility psychiatric sleep and pain disorders.   エレクトロコアは米国のバイオエレクトロニクス企業。主に神経系疾患やリウマチなどの治療のために、非侵襲的な迷走神経刺激法の開発に従事する。同社は成人の偏頭痛およびエピソ―ドクラスタ―頭痛の急性疼痛の治療のために、処方箋のみの迷走神経刺激法のgammaCore(ガンマコア)を開発する。本社所在地はニュ―ジャ―ジ―州ベ―スキング・リッジ。  electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
本社所在地 150 Allen Road Suite 201 Basking Ridge NJ 07920 USA
代表者氏名 J.P. Errico J.P.エリコ
代表者役職名 Chairman of the Board Co-Founder Principal Investor and Chief Science_Strategy Officer
電話番号 +1 973-290-0097
設立年月日 38596
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 64人
url www.electrocore.com
nasdaq_url https://www.nasdaq.com/symbol/ecor
adr_tso
EBITDA EBITDA(百万ドル) -38.75351
終値(lastsale) 13.28
時価総額(marketcap) 391096451.52
時価総額 時価総額(百万ドル) 386.08990
売上高 売上高(百万ドル) 0.99239
企業価値(EV) 企業価値(EV)(百万ドル) 290.26335
当期純利益 当期純利益(百万ドル) -45.14816
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 electroCore Inc. revenues increased 62% to $474K. Net loss increased 52% to $27.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase from $7.9M to $18.8M (expense) Research and development increase of 48% to $6.7M (expense).

 ECORのテクニカル分析


 ECORのニュース

   gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program  2022/04/19 12:00:00 Wallstreet:Online
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore nVNS has been selected for further study under the United States Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) program. The program, which is expected to run through September 2023,
   electroCore rises 4% PM as 1Q22 revenue expected above the consensus  2022/04/12 12:25:35 Seeking Alpha
electroCore (ECOR) climbed 4% PM as 1Q22 revenue from product sales expected to be ~$1.9M vs consensus of $1.74M, an 27% increase Q/Q and 60% growth Y/Y. The Company expects to…
   ElectroCore enters into an exclusive license agreement with Teijin for Japan territory  2022/04/05 12:50:30 Seeking Alpha
ElectroCore (ECOR) up 2% PM on agreement with a Japan based global conglomerate Teijin Limited to license certain exclusive rights to its non-invasive vagus nerve stimulation…
   Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26)  2022/03/14 17:00:00 Benzinga
New York, USA, March 14, 2022 (GLOBE NEWSWIRE) -- Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26) As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others. DelveInsight''s Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market. Key Takeaways from the Global Vagus Nerve Stimulators Market According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period.
   Boom Or Bust? Where Will electroCore Inc. (NASDAQ: ECOR) Stock Go Next?  2022/03/12 12:30:00 Marketing Sentinel
During the last session, electroCore Inc. (NASDAQ:ECOR)’s traded shares were 0.37 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $0.55, reflecting an intraday gain of 5.64% or $0.03. The 52-week high for the ECOR share is $2.44, that puts it down -343.64 … Boom Or Bust? Where Will electroCore Inc. (NASDAQ: ECOR) Stock Go Next? Read More »
   Brokerages Expect electroCore, Inc. (NASDAQ:ECOR) to Announce -$0.06 Earnings Per Share  2021/11/30 11:28:41 Transcript Daily
Wall Street brokerages predict that electroCore, Inc. (NASDAQ:ECOR) will post earnings of ($0.06) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for electroCores earnings, with estimates ranging from ($0.07) to ($0.05). electroCore reported earnings of ($0.14) per share during the same quarter last year, which indicates a positive []
   Golden Stock: Chembio Diagnostics, Inc. (NASDAQ:CEMI), electroCore, Inc. (NASDAQ:ECOR)  2021/11/29 03:41:38 Stock Equity
Chembio Diagnostics, Inc. (CEMI) with the stream of 5.82% also noticed, India electroCore, Inc. (ECOR) encountered a rapid change of -3.36% in the last hour of trading session. Chembio Diagnostics, The post Golden Stock: Chembio Diagnostics, Inc. (NASDAQ:CEMI), electroCore, Inc. (NASDAQ:ECOR) appeared first on Stocks Equity .
   Analysts Expect electroCore, Inc. (NASDAQ:ECOR) Will Announce Earnings of -$0.06 Per Share  2021/11/27 16:38:43 Dakota Financial News
Brokerages expect that electroCore, Inc. (NASDAQ:ECOR) will report earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for electroCores earnings, with estimates ranging from ($0.07) to ($0.05). electroCore posted earnings per share of ($0.14) during the same quarter last year, which would indicate a []
   electroCore Inc. (NASDAQ: ECOR) Down 0.0% From 52-Week Low; YTD Falls -51.42% Heres What To Do Now  2021/11/20 14:30:00 Marketing Sentinel
electroCore Inc. (NASDAQ:ECOR)s traded shares stood at 0.65 million during the last session, with the companys beta value hitting 1.05. At the close of trading, the stocks price was $0.76, to imply a decrease of -1.79% or -$0.01 in intraday trading. The ECOR shares 52-week high remains $3.63, putting it -377.63% down since that peak electroCore Inc. (NASDAQ: ECOR) Down 0.0% From 52-Week Low; YTD Falls -51.42% Heres What To Do Now Read More »
   -$0.06 Earnings Per Share Expected for electroCore, Inc. (NASDAQ:ECOR) This Quarter  2021/11/13 16:28:42 Transcript Daily
Brokerages expect electroCore, Inc. (NASDAQ:ECOR) to announce earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for electroCores earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.07). electroCore reported earnings of ($0.14) per share in the []
   electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients  2021/09/29 12:00:00 Intrado Digital Media
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire TM in patients admitted to the hospital for treatment of COVID-19; is available on MedRxiv and has been submitted for peer review. This study was an investigator-initiated trial conducted at the Hospital Clínico Universitario de Valencia, Spain.
   Stupefying stocks: electroCore, Inc. (NASDAQ:ECOR 5.17%), Cameco Corporation (NYSE:CCJ 3.40%)  2021/09/27 23:40:05 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Stupefying stocks: electroCore, Inc. (NASDAQ:ECOR 5.17%), Cameco Corporation (NYSE:CCJ 3.40%) appeared first on Stocks Equity .
   electroCore to Participate at Upcoming Investor Conferences  2021/09/23 12:00:00 Intrado Digital Media
ROCKAWAY, NJ, Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference.
   electroCore Announces Peter Cuneo as Board Chairman  2021/09/20 12:00:00 Intrado Digital Media
ROCKAWAY, NJ, Sept. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter Cuneo as Chairman of the Board of Directors effective October 1, 2021. Mr. Cuneo was appointed to the Board of Directors in April 2020. He succeeds Mike Atieh, who served as Chairman since April 2020 and who will remain on the Board as an independent director and member of the audit committee.
   Astonishing stocks: Exela Technologies, Inc. (NASDAQ:XELA -1.91%), electroCore, Inc. (NASDAQ:ECOR -2.76%)  2021/09/15 21:49:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Astonishing stocks: Exela Technologies, Inc. (NASDAQ:XELA -1.91%), electroCore, Inc. (NASDAQ:ECOR -2.76%) appeared first on Stocks Equity .

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 エレクトロコア ECOR electroCore Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)